- Home
- LEXX vs VCSA Comparison
LEXX vs VCSA Comparison
Compare LEXX & VCSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEXX
- VCSA
- Stock Information
- Founded
- LEXX 2004
- VCSA 2009
- Country
- LEXX Canada
- VCSA United States
- Employees
- LEXX N/A
- VCSA N/A
- Industry
- LEXX Biotechnology: Pharmaceutical Preparations
- VCSA Computer Software: Prepackaged Software
- Sector
- LEXX Health Care
- VCSA Technology
- Exchange
- LEXX Nasdaq
- VCSA Nasdaq
- Market Cap
- LEXX 49.3M
- VCSA 38.3M
- IPO Year
- LEXX N/A
- VCSA N/A
- Fundamental
- Price
- LEXX $3.10
- VCSA $2.58
- Analyst Decision
- LEXX Strong Buy
- VCSA Buy
- Analyst Count
- LEXX 2
- VCSA 4
- Target Price
- LEXX $11.00
- VCSA $7.50
- AVG Volume (30 Days)
- LEXX 93.9K
- VCSA 84.1K
- Earning Date
- LEXX 11-18-2024
- VCSA 11-05-2024
- Dividend Yield
- LEXX N/A
- VCSA N/A
- EPS Growth
- LEXX N/A
- VCSA N/A
- EPS
- LEXX N/A
- VCSA N/A
- Revenue
- LEXX $411,019.00
- VCSA $1,014,965,000.00
- Revenue This Year
- LEXX $82.02
- VCSA N/A
- Revenue Next Year
- LEXX $95.09
- VCSA N/A
- P/E Ratio
- LEXX N/A
- VCSA N/A
- Revenue Growth
- LEXX 34.05
- VCSA N/A
- 52 Week Low
- LEXX $0.90
- VCSA $2.07
- 52 Week High
- LEXX $6.85
- VCSA $13.00
- Technical
- Relative Strength Index (RSI)
- LEXX 46.94
- VCSA 38.05
- Support Level
- LEXX $2.92
- VCSA $2.47
- Resistance Level
- LEXX $3.39
- VCSA $3.05
- Average True Range (ATR)
- LEXX 0.19
- VCSA 0.24
- MACD
- LEXX -0.01
- VCSA -0.06
- Stochastic Oscillator
- LEXX 39.42
- VCSA 9.12
About LEXX Lexaria Bioscience Corp.
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH has the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. The Company has four reportable segments: Intellectual Property Licensing, B2B Production, Research and Development and Corporate. It earns maximum revenue from Intellectual Property Licensing.
About VCSA Vacasa Inc.
Vacasa Inc is a vacation rental management platform in North America, transforming the vacation rental experience by integrating purpose-built technology with expert local and national teams.